🇺🇸 FDA
Pipeline program

SCENESSE 16 mg implant

CUV105

Phase 3 small_molecule active

Quick answer

SCENESSE 16 mg implant for Vitiligo is a Phase 3 program (small_molecule) at Clinuvel Europe Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Clinuvel Europe Limited
Indication
Vitiligo
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials